参考文献: Naval Daver, Harry Erba, Justin M. Watts, et al. FIRST-IN-HUMAN PHASE 1/2 STUDY OF THE MENIN-MLL INHIBITOR DSP-5336 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LEUKEMIA: UPDATED RESULTS FROM DOSE ESC...
参考文献: Daver N, Zeidner J, Yuda J, et al. First-in-human phase 1/2 study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: updated results from dose escalation. Pr...
1. Sumitomo Pharma announces that DSP-5336 has received FDA fast track designation for the treatment of relapsed or refractory acute myeloid leukemia. News release. July 15, 2024. Accessed July 15, 2024. 2. Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hematology Associ...
参考来源: 1. Sumitomo Pharma announces that DSP-5336 has received FDA fast track designation for the treatment of relapsed or refractory acute myeloid leukemia. News release. July 15, 2024. Accessed July 15, 2024. 2. Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hemat...
TPS7066#Background:DSP-5336, a meninMLLinteraction inhibitor, elicited antitumor activity inMLL–r orNPM1macute leukemia modelsinvitroandinvivo. An open-label, single-arm, phase 1/2 study (NCT04988555) will evaluate the safety and efficacy of DSP-5336 and determine the recommended phase 2 ...
Naval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.
参考来源:‘Sumitomo Pharma announces that DSP-5336 has received FDA fast track designation for the treatment of relapsed or refractory acute myeloid leukemia. News release. July 15, 2024. Accessed July 15, 2024. ‘ 温馨提示:以上资讯由登越药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市...